ES-014
- Generic Name
- ES-014
A Study of ES014 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 15
- Registration Number
- NCT06543056
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Phase 1
Recruiting
- Conditions
- Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05717348
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT05381935
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath